| Name | Title | Contact Details |
|---|
PaxeraHealth (Formerly Paxeramed) is a leading healthcare solution developer based in Boston, MA. We develop a full range of medical imaging solutions including PACS, RIS, VNA, multi-modality workstations, mobile App viewers, patient portal, dental PACS, Vet PACS, advanced visualization, Patient engagement and enterprise solutions. Leveraging technology and staying at the forefront of new healthcare IT technological developments is a high priority for PaxeraHealth. The company develops the next generation medical imaging and Patient engagement technologies designed to automate clients` workflow, elevate patient care and cut healthcare costs.
US Corporate Wellness is the nation`s premier employee wellness provider and one of only 8 national firms to earn Full Accreditation through URAC as a Comprehensive Wellness Provider. We provide a strategy that is tailored to each of our partners to allow maximum engagement and ROI.
IQVIA is a leading global provider of information, innovative technology solutions and contract research services focused on using data and science to help healthcare clients find better solutions for their patients. Formed through the merger of IMS Health and Quintiles, IQVIA offers a broad range of solutions that harness advances in healthcare information, technology, analytics and human ingenuity to drive healthcare forward. IQVIA enables companies to rethink approaches to clinical development and commercialization, innovate with confidence as well as accelerate meaningful healthcare outcomes. IQVIA has approximately 55,000 employees in more than 100 countries, all committed to making the potential of human data science a reality. IQVIAs approach to human data science is powered by the IQVIA CORE™, driving unique actionable insights at the intersection of big data, transformative technology and analytics with extensive domain expertise.
GCG Communications is a Reston, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Bionor Pharma is a leading biotechnology company advancing the first therapeutic vaccine towards a functional cure for HIV. The company`s focus is the research and development of peptide-based vaccines against viral diseases, primarily HIV. Bionor Pharma`s most advanced product candidate is Vacc-4x, which is also the most advanced therapeutic vaccine in the HIV space and has demonstrated a reduction of viral load in a large, randomized, controlled Phase II trial, as well as safety and tolerability. Pharma`s current clinical focus is to explore whether Vacc-4x, used with other medicines as a combination therapy, can reduce the viral load even further, and the company, through collaboration with Celgene, is investigating Vacc-4x and the HDAC inhibitor romidepsin in the REDUC study. In May 2015, Bionor Pharma announced promising results from an interim analysis of Part B of the REDUC study. In the study, Vacc-4x and romidepsin are explored as a possible treatment regimen to reduce the persistent latent viral reservoir in HIV infected patients on anti-retroviral treatment. Results are expected in the second half of 2015. Bionor Pharma is headquartered in Oslo, Norway, with offices in Copenhagen and New York.